Modern Lipid Management: A Literature Review.
alirocumab
atherosclerosis
coronary artery disease
evolocumab
hypercholesterolemia
hyperlipidemia
ldl-c
pcsk9 inhibitors
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
24 Jul 2020
24 Jul 2020
Historique:
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Pro-protein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors are relatively new, non-statin, lipid-lowering drugs that reduce low-density lipoprotein cholesterol (LDL-C) by 60%. PCSK9 inhibitors reduce the blood concentrations of cholesterol by the degradation of LDL receptors, which subsequently extracts cholesterol from cells. This leads to cardiovascular risk reduction in various at-risk populations, including atherosclerotic coronary artery disease. Despite their promise for advanced lipid-lowering ability, cost-effectiveness is a barrier to their routine use. While searching PubMed, we extracted land-mark trials on two of the anti-PCSK9 monoclonal antibodies, alirocumab and evolocumab. When combined with statins or ezetimibe, they show an exponential fall in LDL-C levels, helping achieve target values in high-risk populations and decreasing cardiovascular adverse events. Ongoing research is exploring the long-term efficacy of these antibodies in established coronary artery disease and familial hypercholesterolemia with more prospects for this novel lipid-lowering therapy.
Identifiants
pubmed: 32850243
doi: 10.7759/cureus.9375
pmc: PMC7444996
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e9375Informations de copyright
Copyright © 2020, Malik et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Atherosclerosis. 2016 Jan;244:138-46
pubmed: 26638010
Int J Cardiol. 2014 Sep;176(1):55-61
pubmed: 25037695
Atherosclerosis. 2018 Sep;276:124-130
pubmed: 30059843
Am J Med. 2019 Nov;132(11):1320-1326.e1
pubmed: 31278931
Trends Cardiovasc Med. 2020 Mar 12;:
pubmed: 32205033
JAMA. 2014 May 14;311(18):1870-82
pubmed: 24825642
JAMA Cardiol. 2020 Apr 29;:
pubmed: 32347887
IUBMB Life. 2015 Dec;67(12):954-65
pubmed: 26601917
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
J Am Coll Cardiol. 2019 Oct 29;74(17):2132-2146
pubmed: 31648705
Future Cardiol. 2015;11(1):27-37
pubmed: 25606700
Drug Metab Pharmacokinet. 2004 Oct;19(5):375-80
pubmed: 15548849
J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8
pubmed: 26030325
JAMA. 2012 Dec 19;308(23):2497-506
pubmed: 23128163
Eur Heart J Cardiovasc Pharmacother. 2020 Apr 10;:
pubmed: 32275743
Acta Med Port. 2020 Jan 3;33(1):49-57
pubmed: 31928603
Circ J. 2014;78(5):1073-82
pubmed: 24662398
Vasc Health Risk Manag. 2017 Jul 06;13:247-253
pubmed: 28740397
Am J Cardiol. 2017 Sep 15;120(6):931-939
pubmed: 28750828
Eur Heart J. 2015 Nov 14;36(43):2996-3003
pubmed: 26330422
Circ J. 2017 Jun 23;81(7):1029-1035
pubmed: 28367845
Circulation. 2018 Nov 20;138(21):2315-2325
pubmed: 30571575
Atherosclerosis. 2020 Jan;292:231-233
pubmed: 31784033
J Am Coll Cardiol. 2014 Jun 17;63(23):2541-2548
pubmed: 24694531
J Lipid Res. 2017 Aug;58(8):1722-1729
pubmed: 28611099
Can J Cardiol. 2011 Sep-Oct;27(5):635-62
pubmed: 21963058
Am Heart J. 2016 Aug;178:135-44
pubmed: 27502861
Drugs. 2018 Mar;78(3):287-291
pubmed: 29396831
J Clin Lipidol. 2018 Sep - Oct;12(5):1199-1207
pubmed: 30318065
J Clin Lipidol. 2015 Nov-Dec;9(6):758-769
pubmed: 26687696